Page 62 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New toolkit aims to improve quality of thrombosis data in COVID-19 trials

E-Mail The ASH Research Collaborative (ASH RC) and the International Society of Haemostasis and Thrombosis (ISTH), two organizations with multidisciplinary expertise in blood clotting and bleeding disorders, have developed a toolkit to help clinical researchers from across medical disciplines design clinical trials that further the understanding of blood clotting events associated with COVID-19. The new Toolkit for the Collection of Thrombosis-Related Data Elements in COVID-19 Clinical Studies, published today in Blood Advances, defines a series of endpoints - events or outcomes that are measured in a clinical study - that should be included in study design to collect and analyze important, relevant, and standardized data on dangerous blood clots that form in the veins or arteries of patients with COVID-19. The goal of this initiative is to maximize high-quality collection of COVID-19-associated clotting and bleeding events across diverse medical fields, such as internal medici

United statesStephanie leeJeffrey weitzAmerican society of hematologyResearch collaborativeInternational society of haemostasisClinical trials networkFred hutchinson cancer research instituteInternational societyThrombosis related data elementsBlood advancesAmerican societyData elementsData hubSickle cell diseaseஒன்றுபட்டது மாநிலங்களில்

GT Biopharma And Cytovance Biologics Announce Milestone Achievement

Published: Dec 17, 2020 BEVERLY HILLS, Calif., Dec. 17, 2020 /PRNewswire/ GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) a company focused on developing innovative therapeutic treatments based on its proprietary NK cell engager (TriKE™) platform, announced today that Cytovance, a USA-based contract development and manufacturing organization (CDMO) and a subsidiary of the Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ( Hepalink ), have reached an agreement for license rights to use certain bacterial and mammalian cell lines and for GMP manufacturing services performed to date regarding the Company s TriKE™ product candidates. Under the terms of the partnership agreement entered into between the companies, Cytovance is the exclusive GMP manufacture for three of the Company s TriKE™ therapeutic product candidates. Cytovance will manufacture TriKE™ in accordance with GMP using Cytovance s proprietary Keystone® bacterial or mammalian expression systems. Subject

United statesAnthony cataldoBeverly hillsShenzhen hepalink pharmaceutical group co ltdSource gt biopharma incAmerican society of hematologyExchange commissionCompany codesUniversity of minnesotaGt biopharma incCompany triUnited states basedCytovance theChief executive officerAmerican societySecurities act

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline

National Institute of Health (NIH), for use in the pre-clinical ONKT101 program, for relapsed/refractory B cell malignancies ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has secured three new exclusive option license agreements which strengthen its off-the-shelf, dual-targeted natural killer (NK) cell therapy platform and extend its pre-clinical pipeline to four programs across both hematological and solid tumors. The first option agreement, with Cellerant Therapeutics, gives exclusive rights to a humanized CLEC12A scFv binder. CLEC12A is strongly expressed by blasts in the majority of AML patients. The option to license has enabled ONK to expand its pre-clinical product portfolio, launching a fourth program (ONKT104). This dual-targeted approach combines the CLEC12A CAR with a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting death receptor 4 (DR4).

San diegoUnited statesSeamus mulliganGlycotope gmbAmerican society of hematologyNational institute of healthTherapeutics incTherapeutics ltdCellerant therapeuticsGlycotope gmbhNational instituteProf michaelo dwyerChris nowersKite pharma headChief executive officerAmerican society

Global Sarcoma Drugs Market Size Could Reach $1 2 Billion By 2023

Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023 Financialnewsmedia.com News Commentary PALM BEACH, Fla., Dec. 17, 2020 /PRNewswire/ Soft tissue sarcoma (STS) is a rare type of cancer that develops in tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. Generally occurring in the muscles, tissues, and blood vessels that protect, support and surround the organs. Moreover, it is not categorized as tumor, but can be life-threatening if the cancer spreads to other parts of the body. Currently, there are very few products approved for the treatment of soft tissue sarcoma, while the cases continue to increase. Industry reports say that the total number of soft tissue sarcoma patients in the seven major global markets is estimated to reach 46,864 by 2030 from 37,393 in 2019 at a CAGR of 2.0%. Increase in the incidence and prevalence of different types of cancers, rising cases of soft tissue sarcoma, increasing R&D activities on drugs and other the

United statesKostenloser wertpapierhandelWalter klempMichael castagnaThomas hofmannCardiff oncology incRigel pharmaceuticals incMoleculin biotech incDrug administrationFn media groupExchange commissionAmerican society of hematologyView researchMannkind corporationSecurities exchangeQrumpharma inc

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline - Press Release

ONK Therapeutics Announces Three Exclusive Option License Agreements, Which Extend and Strengthen its Dual-Targeted NK Cell Therapy Pipeline - Press Release
digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesSeamus mulliganGlycotope gmbSue charlesAmerican society of hematologyTherapeutics incTherapeutics ltdBusiness wireCellerant therapeuticsProf michaelo dwyerChris nowersKite pharma headChief executive officerAmerican societyJohnson innovation